{
    "startDate": "2020-01-01",
    "endDate": "2020-06-30",
    "year": "2020",
    "quarter": "Q2",
    "symbol": "LIFE",
    "data": {
        "bs": [
            {
                "label": "Cash and cash equivalents",
                "concept": "CashAndCashEquivalentsAtCarryingValue",
                "unit": "usd",
                "value": 21632000
            },
            {
                "label": "Available-for-sale investments",
                "concept": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
                "unit": "usd",
                "value": 19802000
            },
            {
                "label": "Other receivables",
                "concept": "OtherReceivablesNetCurrent",
                "unit": "usd",
                "value": 831000
            },
            {
                "label": "Prepaid expenses",
                "concept": "PrepaidExpenseCurrent",
                "unit": "usd",
                "value": 1575000
            },
            {
                "label": "Current assets:",
                "concept": "AssetsCurrent",
                "unit": "usd",
                "value": 43840000
            },
            {
                "label": "Property and equipment, net",
                "concept": "PropertyPlantAndEquipmentNet",
                "unit": "usd",
                "value": 1136000
            },
            {
                "label": "Right-of-use assets",
                "concept": "OperatingLeaseRightOfUseAsset",
                "unit": "usd",
                "value": 2461000
            },
            {
                "label": "Other assets",
                "concept": "OtherAssetsNoncurrent",
                "unit": "usd",
                "value": 125000
            },
            {
                "label": "Assets",
                "concept": "Assets",
                "unit": "usd",
                "value": 47562000
            },
            {
                "label": "Accounts payable",
                "concept": "AccountsPayableCurrent",
                "unit": "usd",
                "value": 603000
            },
            {
                "label": "Accrued expenses",
                "concept": "AccruedLiabilitiesCurrent",
                "unit": "usd",
                "value": 2809000
            },
            {
                "label": "Contract liability",
                "concept": "ContractWithCustomerLiabilityCurrent",
                "unit": "usd",
                "value": 201000
            },
            {
                "label": "Current portion of operating lease liability",
                "concept": "OperatingLeaseLiabilityCurrent",
                "unit": "usd",
                "value": 807000
            },
            {
                "label": "Term loans, net of issuance costs and discount (Note 4)",
                "concept": "LongTermDebtCurrent",
                "unit": "usd",
                "value": 4976000
            },
            {
                "label": "Grant fund liability current.",
                "concept": "life:GrantFundLiabilityCurrent",
                "unit": "usd",
                "value": 403000
            },
            {
                "label": "Current liabilities:",
                "concept": "LiabilitiesCurrent",
                "unit": "usd",
                "value": 9799000
            },
            {
                "label": "Long-term operating lease liability, net of current portion",
                "concept": "OperatingLeaseLiabilityNoncurrent",
                "unit": "usd",
                "value": 1825000
            },
            {
                "label": "Commitments and contingencies (Note 4)",
                "concept": "CommitmentsAndContingencies",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Common stock, $0.001 par value per share; 21,425,000 and 10,714,286 authorized shares as of June 30, 2020 and December 31, 2019, respectively; issued and outstanding shares \u2013 9,383,425 and 3,891,787 as of June 30, 2020 (unaudited) and December 31, 2019, respectively",
                "concept": "CommonStockValue",
                "unit": "usd",
                "value": 9000
            },
            {
                "label": "Additional paid-in capital",
                "concept": "AdditionalPaidInCapital",
                "unit": "usd",
                "value": 363132000
            },
            {
                "label": "Accumulated other comprehensive loss",
                "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
                "unit": "usd",
                "value": -44000
            },
            {
                "label": "Accumulated deficit",
                "concept": "RetainedEarningsAccumulatedDeficit",
                "unit": "usd",
                "value": -326997000
            },
            {
                "label": "Stockholders\u2019 equity:",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": 36100000
            },
            {
                "label": "Noncontrolling interest in Pangu BioPharma Limited",
                "concept": "MinorityInterest",
                "unit": "usd",
                "value": -162000
            },
            {
                "label": "Total stockholders' equity",
                "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": 35938000
            },
            {
                "label": "Liabilities and Stockholders\u2019 Equity",
                "concept": "LiabilitiesAndStockholdersEquity",
                "unit": "usd",
                "value": 47562000
            }
        ],
        "cf": [
            {
                "label": "Consolidated net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -4695000
            },
            {
                "label": "Depreciation and amortization",
                "concept": "DepreciationDepletionAndAmortization",
                "unit": "usd",
                "value": 313000
            },
            {
                "label": "Stock-based compensation",
                "concept": "AllocatedShareBasedCompensationExpense",
                "unit": "usd",
                "value": 801000
            },
            {
                "label": "Debt discount accretion and non-cash interest expense",
                "concept": "AccretionExpense",
                "unit": "usd",
                "value": 239000
            },
            {
                "label": "Accretion of discount of available-for-sale investment securities",
                "concept": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
                "unit": "usd",
                "value": 11000
            },
            {
                "label": "Operating lease right of use asset amortization.",
                "concept": "life:OperatingLeaseRightOfUseAssetAmortization",
                "unit": "usd",
                "value": 407000
            },
            {
                "label": "Loss (gain) on disposal of property and equipment",
                "concept": "GainLossOnSaleOfPropertyPlantEquipment",
                "unit": "usd",
                "value": -6000
            },
            {
                "label": "Other receivables",
                "concept": "IncreaseDecreaseInOtherReceivables",
                "unit": "usd",
                "value": 731000
            },
            {
                "label": "Prepaid expenses and other assets",
                "concept": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
                "unit": "usd",
                "value": 894000
            },
            {
                "label": "Accounts payable and accrued expenses",
                "concept": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
                "unit": "usd",
                "value": 186000
            },
            {
                "label": "Contract liability",
                "concept": "IncreaseDecreaseInContractWithCustomerLiability",
                "unit": "usd",
                "value": -7000
            },
            {
                "label": "Increase (decrease) in operating lease liability.",
                "concept": "life:IncreaseDecreaseInOperatingLeaseLiability",
                "unit": "usd",
                "value": -362000
            },
            {
                "label": "Grant funding liability.",
                "concept": "life:GrantFundingLiability",
                "unit": "usd",
                "value": -403000
            },
            {
                "label": "Cash flows from operating activities:",
                "concept": "NetCashProvidedByUsedInOperatingActivities",
                "unit": "usd",
                "value": -4345000
            },
            {
                "label": "Purchases of property and equipment",
                "concept": "PaymentsToAcquirePropertyPlantAndEquipment",
                "unit": "usd",
                "value": 185000
            },
            {
                "label": "Purchases of available-for-sale investment securities",
                "concept": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
                "unit": "usd",
                "value": 18011000
            },
            {
                "label": "Maturities of available-for-sale investment securities",
                "concept": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
                "unit": "usd",
                "value": 20150000
            },
            {
                "label": "Proceeds from sale of property and equipment",
                "concept": "ProceedsFromSaleOfPropertyPlantAndEquipment",
                "unit": "usd",
                "value": 3000
            },
            {
                "label": "Cash flows from investing activities:",
                "concept": "NetCashProvidedByUsedInInvestingActivities",
                "unit": "usd",
                "value": 1957000
            },
            {
                "label": "Proceeds from issuance of common stock under employee stock purchase plan.",
                "concept": "life:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan",
                "unit": "usd",
                "value": 6000
            },
            {
                "label": "Proceeds from issuance of common stock through at market offering net of offering costs.",
                "concept": "life:ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts",
                "unit": "usd",
                "value": 25000
            },
            {
                "label": "Proceeds from issuance of common stock through underwritten follow-on offering, net of offering costs.",
                "concept": "life:ProceedsFromIssuanceOfCommonStockThroughUnderwrittenFollowOnOfferingNetOfOfferingCosts",
                "unit": "usd",
                "value": 18779000
            },
            {
                "label": "Repayments on borrowings",
                "concept": "RepaymentsOfDebt",
                "unit": "usd",
                "value": 4000000
            },
            {
                "label": "Cash flows from financing activities:",
                "concept": "NetCashProvidedByUsedInFinancingActivities",
                "unit": "usd",
                "value": 14810000
            },
            {
                "label": "Net change in cash and cash equivalents",
                "concept": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
                "unit": "usd",
                "value": 12422000
            }
        ],
        "ic": [
            {
                "label": "Total revenues",
                "concept": "RevenueFromContractWithCustomerExcludingAssessedTax",
                "unit": "usd",
                "value": 8254000
            },
            {
                "label": "Research and development",
                "concept": "ResearchAndDevelopmentExpense",
                "unit": "usd",
                "value": 7977000
            },
            {
                "label": "General and administrative",
                "concept": "GeneralAndAdministrativeExpense",
                "unit": "usd",
                "value": 4736000
            },
            {
                "label": "Operating expenses:",
                "concept": "OperatingExpenses",
                "unit": "usd",
                "value": 12713000
            },
            {
                "label": "Loss from operations",
                "concept": "OperatingIncomeLoss",
                "unit": "usd",
                "value": -4459000
            },
            {
                "label": "Total other expense, net",
                "concept": "NonoperatingIncomeExpense",
                "unit": "usd",
                "value": -236000
            },
            {
                "label": "Consolidated net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -4695000
            },
            {
                "label": "Net loss attributable to noncontrolling interest in Pangu BioPharma Limited",
                "concept": "NetIncomeLossAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": -2000
            },
            {
                "label": "Net loss attributable to noncontrolling interest in Pangu BioPharma Limited",
                "concept": "NetIncomeLoss",
                "unit": "usd",
                "value": -4693000
            },
            {
                "label": "Net loss per share, basic and diluted",
                "concept": "EarningsPerShareBasicAndDiluted",
                "unit": "usd/shares",
                "value": -0.58
            },
            {
                "label": "Shares used in computing net loss per share, basic and diluted",
                "concept": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
                "unit": "shares",
                "value": 8119612
            },
            {
                "label": "Change in unrealized gain (loss) on available-for-sale investments, net of tax",
                "concept": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
                "unit": "usd",
                "value": -4000
            },
            {
                "label": "Comprehensive loss",
                "concept": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": -4699000
            },
            {
                "label": "Comprehensive loss attributable to noncontrolling interest Pangu BioPharma Limited",
                "concept": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": -2000
            },
            {
                "label": "Comprehensive loss",
                "concept": "ComprehensiveIncomeNetOfTax",
                "unit": "usd",
                "value": -4697000
            }
        ]
    }
}